Print（PDF/58KB） Jul. 30, 2014 Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ending September 30, 2014
Osaka, Japan, July 30, 2014 - Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; Securities Codes: 4506, First Section of TSE) announced today that it has revised its financial forecasts for the Half-year ending September 30, 2014 as summarized below, in light of recent performance trends and other factors.
- Revisions to the Forecasts of Consolidated Financial Results for the Half-year ending September 30, 2014 (April 1, 2014 to September 30, 2014)
(Amounts in Japanese yen million, unless otherwise specified)
| Net sales | Operating income | Ordinary income | Net income | Earnings per share | |
|---|---|---|---|---|---|
| Previous Forecasts (A) | 178,000 | 12,000 | 11,500 | 6,300 | ¥15.86 |
| Revised Forecasts (B) | 178,000 | 12,000 | 11,500 | 11,000 | ¥27.69 |
| Variance in amount (B)－(A) |
－ | － | － | 4,700 | |
| Variance in percent (%) | － | － | － | 74.6 | |
| [Reference] Same period a year ago (Half-year ending September 30, 2013) |
181,396 | 17,435 | 17,408 | 8,697 | ¥21.89 |
- Reasons for the revisions
Accrual of an extraordinary income in connection with disposal of idle assets which was anticipated for the second half of the fiscal year is now expected to take place during the July - September 2014 period. The forecasted net income for the first half of fiscal 2014 is now revised to 11,000 million yen from 6,300 million yen. There is no change in the forecasts for the full year.
Cautionary statement:
Forecasts shown above are based on management's assumptions and beliefs in light of the information currently available, and involve risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including economic conditions.
Inquiries from the Press